Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: Correlation with ofloxacin susceptibility

Microbial Drug Resistance

Volumn 12, Issue 1, 2006, Pages 7-11

  Kam, Kai Man ^a   Yip, Chi Wai ^a   Cheung, Tze Leung ^a   Tang, Hei Sing ^a   Leung, Oi Chi ^a   Chan, Mei Yuk ^a  

^a DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GLYCINE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DNA SEQUENCE; DRUG EFFICACY; DRUG MONITORING; GENE MUTATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLINES;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 33646053127     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2006.12.7     Document Type: Article

References (32)

1. Alvirez-Freites, E.J., J.L. Carter, and M.H. Cynamon. 2002. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:1022-1025.
2. Capitano, B., H.M. Mattoes, E. Shore, A. O'Brien, S. Braman, C. Sutherland, and D.P. Nicolau. 2004. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125:965-973.
3. Cheng, A.F.B., W.W. Yew, E.W.C. Chan, M.L. Chin, M.M.M. Hui, and R.C.Y. Chan. 2004. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 48:596-601.
4. Dauendorffer, J.N., I. Guillemin, A. Aubry, C. Truffot-Pernot, W. Sougakoff, V. Jarlier, and E. Cambau. 2003. Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. J. Clin. Microbiol. 41:1311-1315.
5. Escalante, P., S. Ramaswamy, H. Sanabria, H. Soini, O. Valiente-Castillo, and J.M. Musser. 1998. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber. Lung Dis. 79:111-118.
6. Gosling, R.D., L.O. Uiso, N.E. Sam, E. Bongard, E.G. Kanduma, M. Nyindo, R.W. Morris, and S.H. Gillespie. 2003. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 168:1342-1345. (Epub 2003 Aug 13.)
7. Hansen, G.T., K. Metzler, K. Drlica, and J.M. Blondeau. 2003. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47:440-441.
8. Heifet, L.B. 1991. Antituberculosis drugs: antimicrobial activity in vitro. In L.B. Heifet (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Boca Raton, FL, pp. 13-57.
9. Heifet, L.B. 1991. Drug susceptibility tests in the management of chemotherapy of tuberculosis. In L.B. Heifet (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Boca Raton, FL, pp. 89-121.
10. Heifet L.B. 1991. Drug combinations. In L. Heifet (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Boca Raton, FL, pp. 179-199.
11. Hu, Y., A.R. Coates, and D.A. Mitchison. 2003. Sterilizing activities of fluoroquinolones against rifampicin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:653-657.
12. Iseman, M.D., and G.A. Huitt. 2000. Treatment of multidrug-resistant tuberculosis. In I. Bastian and F. Portaels (eds.), Multidrug-resistant tuberculosis. Kluwer Academic Publishers, The Netherlands, pp. 175-190.
13. Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis, Antimicrob. Agents Chemother. 42:2066-2069.
14. Kam, K.M., and C.W. Yip. 2004. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus. Int. J. Tuberc. Lung Dis. 8:760-766.
15. Kocagoz, T., C.J. Hackbarth, I. Unsal, E.Y. Rosenberg, H. Nikaido, and H.F. Chambers. 1996. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 40:1768-1774.
16. Lee, A.S., L.L. Tang, I.H. Lim, and S.Y. Wong. 2002. Characterization of pyrazinamide and ofloxacin resistance among drug-resistant Mycobacterium tuberculosis isolates from Singapore. Int. J. Infect. Dis. 6:48-51.
17. Lober, S., S. Ziege, M. Rau, G. Schreiber, A. Mignot, P. Koeppe, and H. Lode. 1999. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob. Agents Chemother. 43:1067-1071.
18. Lubasch, A., I. Keller, K. Borner, P. Koeppe, and H. Lode. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44:2600-2603.
19. Musser, J.M. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev. 8:496-514.
20. Nuermberger, E.L., T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R.J. O'Brien, A.A. Vernon, R.E. Chaisson, W.R. Bishai, and J.H. Grosset. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170:1131-1134. (Epub 2004 Aug 11.)
21. Onodera, Y., M. Tanaka, and K. Sato. 2001. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 47:447-450.
22. Pletz, M.W.R., A. De Roux, A. Roth, K.-H. Neumann, H. Mauch, and II. Lode. 2004. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis; a prospective, randomized study. Antimicrob. Agents Chemother. 48:780-782.
23. Rodriguez, J.C., L. Cebrian, M. Lopez, M. Ruiz, I. Jimenez, and G. Royo. 2004. Mutant prevention concentration: comparison of fluoroquinolones and Hnezolid with Mycobacterium tuberculosis. J. Antimicrob. Chemother. 53:441-444.
24. Rodriguez, J.C., M. Ruiz, M. Lopez, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents. 20:464-467.
25. Soman, A., D. Honeybourne, J Andrews, G. Jevons, and R. Wise. 1999. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44:835-838.
26. Tahaoglu, K., T. Torun, T. Sevim, G. Atac, A. Kir, L. Karasulu, I. Ozmen, and N. Kapakli. 2001. The treatment of multidrug-resistant tuberculosis in Turkey. N. Engl. J. Med. 345:170-174.
27. Takiff, H.E., L. Salazar, C. Guerrero, W. Philipp, W.M. Huang, B. Kreiswirth, S.T. Cole, W.R. Jacobs Jr., and A. Telenti. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780.
28. Tortoli, E., D. Dionisio, and C. Fabbri. 2004. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains. J. Chemother. 16:334-336.
29. Valerio, G., P. Bracciale, V. Manisco, M. Quitadamo, G. Legari, and S. Bellanova. 2003. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J. Chemother. 15:66-70.
30. Xu, C., B.N. Kreiswirth, S. Sreevatsan, J.M. Musser, and K. Drlica. 1996. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J. Infect. Dis. 174:1127-1130.
31. Yew, W.W., C.K. Chan, C.H. Chau, C.M. Tam, C.C. Leung, P.C. Wong, and J. Lee. 2000. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117:744-751.
32. Yu, M.C., J. Suo, T.P. Lin, and K.T. Luh. 1997. In vitro activity of ofloxacin against Mycobacterium tuberculosis. J. Formos. Med. Assoc. 96:13-16.